InvestSMART

Imagion Biosystems Limited (ASX:IBX)

ALERT: Price-sensitive ASX Announcement for IBX
Current share price for IBX : $0.012 -0.021 (-63.64%)+
Announcement
Release
8 Jan 2026 10:07AM
Price at Release
$0.033
Full Release
download
Summary
Imagion Biosystems Limited, operating on the ASX as IBX, has announced key updates concerning its Convertible Securities Agreement with Mercer Street Global Opportunity Fund, LLC. The first tranche of notes has been entirely converted, leading to the issuance of 3,048,484 ordinary shares to Mercer. Amendments have been made to the second tranche notes, including a $300,000 payment to reduce the outstanding balance and an extension of the maturity date to 28 February 2026. Any balance remaining by the new maturity date is to be converted to shares. This agreement, originating on 7 March 2023, consists of five tranches and plays a part in Imagion's efforts to enhance healthcare outcomes through its MagSense® imaging technology. An updated summary of these financial instruments will be detailed in the upcoming December 2025 Quarterly Activities Report.
Key Points
  • Imagion Biosystems Limited, listed as ASX: IBX, announced updates regarding its Convertible Securities Agreement with Mercer Street Global Opportunity Fund, LLC.
  • The First Tranche Notes of the agreement have been fully converted and extinguished, resulting in the issuance of 3,048,484 ordinary shares to Mercer Street.
  • Amendments to the Second Tranche Notes include a payment of $300,000 reducing the balance and extending the maturity date to 28 February 2026.
  • The remaining balance of the Second Tranche Notes will be converted to shares if not converted by Mercer Street before the new maturity date.
  • The Convertible Securities Agreement was initially entered on 7 March 2023, and involves five tranches of convertible notes.
  • An updated summary of the Notes will be provided in the December 2025 Quarterly Activities Report.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.